Deliver Biosciences

Deliver Biosciences is a private, pre-clinical stage biotech founded in 2021, pioneering a targeted nanoparticle platform for in vivo cell and gene therapy. The technology is designed to deliver diverse genetic payloads (e.g., DNA, mRNA for CARs) directly to specific cell types within the body, potentially bypassing the complex and costly ex vivo manufacturing of current cell therapies. Led by a scientifically strong founding team and advised by industry veterans, the company's first program targets the creation of in vivo CAR-T cells for oncology, aiming to democratize access to these potent treatments. Its platform approach holds promise for a broad range of serious diseases currently lacking curative options.

Targeted nanoparticle-based delivery platform for in vivo genetic engineering, designed to transport DNA and mRNA payloads to specific cell types while avoiding off-target organs like the liver.

Deliver operates in a highly competitive field with numerous players developing viral and non-viral delivery technologies for genetic medicines. Key competitors include other nanoparticle-focused biotechs (e.g., ReCode Therapeutics, GenEdit), lipid nanoparticle (LNP) innovators, and companies developing in vivo gene editing therapies. Its success will depend on demonstrating superior targeting, safety, and manufacturability compared to these alternatives.